Journal
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH
Volume 15, Issue 7, Pages 1353-1360Publisher
PHARMACOTHERAPY GROUP
DOI: 10.4314/tjpr.v15i7.1
Keywords
Chitosan; Docetaxel; Alendronate; Nanocarriers; Sustained-release kinetics; Polylactide-co-glycolide; Osteosarcoma; Cellular uptake
Categories
Funding
- Technical Grant of KaiFeng Central Hospital, China
Ask authors/readers for more resources
Purpose: To develop docetaxel (DTX)-and alendronate (ALN)-loaded, chitosan (CS)-conjugated polylactide-co-glycolide (PLGA) nanoparticles (NPs) to increase therapeutic efficacy in osteosarcoma cells. Methods: Drug-loaded PLGA NPs were prepared by nanoprecipitation and chemically conjugated by the carboxylic group of PLGA to the amine-bearing CS polymer. The nanocarrier was characterized by dynamic light scattering, transmission electron microscopy, scanning electron microscopy, and differential scanning calorimetry as well as by in vitro drug release and cell culture studies. Results: NP size was within the tumour targeting range (similar to 200 nm) with an effective positive charge (20 mV), thus increasing cellular uptake efficiency. Morphological analysis revealed clear spherical particles with uniform dispersion. The NPs exhibited identical sustained release kinetics for both DTX and ALN. CS-conjugated PLGA with dual-drug-loaded (DTX and AL) NPs showed typical time-dependent cellular uptake and also displayed superior cytotoxicity in MG-63 cells compared with blank NPs, which were safe and biocompatible. Conclusion: Combined loading of DTX and ALN in NPs increased the therapeutic efficacy of the formulation for osteosarcoma treatment, thus indicating the potential benefit of a combinatorial drug regimen using nanocarriers for effective treatment of osteosarcoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available